NeuroVive discontinues development of CicloMulsion for

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 13, 2016 at 2:45 AM

NeuroVive discontinues development of CicloMulsion for acute kidney injury

Lund, Sweden, October 13, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced results from the exploratory clinical phase II study CiPRICS. The results clearly show that patients treated with CicloMulsion prior to open heart surgery experience no benefit compared to placebo in the prevention of acute kidney injury (AKI). As a result, NeuroVive will discontinue the development of CicloMulsion for AKI. The exploratory CiPRICS study, aimed at preventing AKI in patients undergoing open heart surgery, did not reach the primary objective. In contrast, patients in the active dose group showed a transient, but statistically significant increase in the biomarkers P-cystatin C and P-creatinine compared to placebo. No unexpected tolerability issues were observed and the overall frequencies of serious adverse events were comparable to those observed in the placebo group. "Since the overall goal for this study was to offer a preventive treatment to patients at risk of developing AKI, the outcome of the study was a disappointment. However, the CiPRICS study has given us very important information about ciclosporin treatment in this patient population. Also, we have appreciated the fruitful and close collaboration with the NeuroVive clinical team", says Sponsor-Investigator, Associate Professor Henrik Bjursten M.D. Ph.D., Department of Cardiothoracic Surgery, Anesthesia and Intensive Care at Skåne University Hospital in Lund, Sweden. Given the current findings, NeuroVive has decided to discontinue the development of CicloMulsion in AKI and redirect resources to its other development assets. NeuroVive continues to progress its opportunities within mitochondrial medicine, an area with high unmet medical needs. The ciclosporin (NeuroSTAT) development program in traumatic brain injury (TBI) will proceed. NeuroVive will continue development of its unique non-Ciclosporin based cyclophilin inhibitors for organ protection and other unrelated indications. In addition to these high-value possibilities, NeuroVive has several other promising early projects with different, novel modes of action within the area of mitochondrial medicine. "The CiPRICS study has been excellently conducted by the team, led by Associate Professor Bjursten at Skåne University Hospital, with clear results. Moreover, it has verified the effectiveness of the network partnership model for NeuroVive’s early clinical development”, says NeuroVive’s CEO Erik Kinnman. “We will continue to develop and build our portfolio, and I see several potential upcoming milestone events in our strong and diversified mitochondrial medicine portfolio.” A web cast for presentation of the study results will be held at 3:00 p.m. today. To listen to the presentation please visit https://wonderland.videosync.fi/2016-10-13-ne...conference. To call -in please use one of the following numbers: Sweden: +46856642690 UK: +442030089815 US: +18558315946. Dr. Bjursten will this afternoon give an oral presentation with the title Ciclosporin to Protect Renal Function In Cardiac Surgery (CiPRICS). A Double Blind, Randomised, Placebo Controlled, Proof of Concept Study at the Swedish Thorax meeting in Malmö. For further information about the program, please visit the conference web site: http://www.malmokongressbyra.se/svenska_thoraxmotet/program. About CiPRICS The CiPRICS study (Ciclosporin to Protect Renal Function In Cardiac Surgery) was a double-blind, randomized and placebo-controlled exploratory phase II study that investigated NeuroVive’s candidate drug CicloMulsion in the prevention of acute kidney injury (AKI) in open heart surgery. The primary endpoint was relative changes in P-cystatin C between the treatment groups three days after surgery. Secondary endpoints included evaluation of P-creatinine and other biomarkers of kidney, heart and brain injury. The study encompassed 155 patients who were treated with CicloMulsion or placebo prior to coronary artery bypass surgery (CABG) at the Department of Cardiothoracic Surgery, Anesthesia and Intensive Care at Skåne University Hospital in Lund, Sweden. The study was investigator-initiated and performed by Skåne University Hospital with support from NeuroVive. More information about the study is published in the public database www.ClinicalTrials.gov. About NeuroVive NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc. market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. For investor relations and media questions, please contact: Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or ir.usa@neurovive.com. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on October 13, 2016.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

F&G Annuities Unveils $100M Buyback Program

By Lucas Young Updated Nov 6, 2026 Category News Views 100

A Bold Move with a Three-Year Horizon F&G Annuities & Life just lobbed a hefty curveball into the investing field with a fresh $100 million share buyback scheme, which kicked off on November 5, 2026. Now, anytime a company dangles repurchase programs in front of investors, it's a red flag indicator—or a green light, depending on how you see it. This maneuver helps...

CassTime's AI Solution Eases Global Parts Market Strains

Driving Innovation in the Auto Aftermarket When car parts become a global jigsaw puzzle, you need more than wrenches to solve it. Enter CassTime with its AI-driven 'T+D Solution'—a tangible answer to the woes of data matching and repair capability bottlenecks plaguing the automotive aftermarket worldwide. Taming the Global Parts Beast Pull back the curtain on AAPEX 2026...

SAGA Metals Enters Decision-Making Circles in Canada

Stepping into the Big Leagues Seems like SAGA Metals is making a gutsy move, stepping into some heavy-hitting circles. They just hitched their wagon to the Canadian Chamber of Commerce's Critical Minerals Council. That's not just a foot in the door; that's walking right into the room where national policy gets cooked up. Joining forces here could be their ticket to...

West Virginia Water Gains: Central Grove Upgrade Begins

Kickoff at Central Grove: What’s Brewing? Ever wander through Kearneysville, W.Va., and wonder what’s going on with that bustling crew near Goldenrod Drive? The folks at West Virginia American Water have kicked off groundwork for the much-anticipated Central Grove Water Treatment Plant. This, comrades, isn’t just some shiny new shed we’re talking about. Oh no,...

AZZ Inc.'s 2026 Sustainability Report: A Closer Look

Diving into AZZ's Sustainability Commitment AZZ Inc., known in the trading circles as NYSE:AZZ, has just dropped its 2026 Sustainability Report and it’s quite the document to chew on. This ain't your typical corporate fluff. Tom Ferguson, the man steering the AZZ ship, laid it down plain and simple. This report isn’t just about ticking boxes for ESG; it’s reflecting...

OncoC4's Cesalatamig: Promising Results in NSCLC Trials

Hope in Persistence: Cesalatamig in the Spotlight Swinging through the medical landscape like a seasoned fighter, OncoC4's recent revelations at the SITC 2026 give investors and doctors a reason to pay close attention. We're sizing up their investigational drug, cesalatamig, which flaunts a solid objective response rate of 33% among non-small cell lung cancer (NSCLC)...

Illinois Greenlights Major Water Utility Merger

Regulators Signal Green Light for Major Merger When was the last time a deal didn't hit some bumps in the regulatory road? This time, American Water and Essential Utilities are keeping the wheels greased, with the Illinois Commerce Commission giving their merger proposal a thumbs up. It feels like a classic case of utilities sticking to their market playbook—get bigger...

Louisiana's Musical Legacy Gets a Boost from Foundation

Preserving the Tunes of the Bayou Well, if that ain't music to your ears! The Louisiana First Horizon Foundation is sliding into the spotlight with news that's bound to strike a chord with any lover of the state's iconic rhythms. They're diving in deep, backing the Louisiana Music Museum right in the heart of Lafayette. Now, that ain't just another charity stunt; it's a...

Brian Long Exits Atlantic Bridge for US Tech Fund

Well, here we go again with another shake-up in the tech investment world. Brian Long, a name that's been whispered around more than a few boardroom tables, is dropping out of Atlantic Bridge to start his own gig across the pond in the United States. If you're tracking numbers, Atlantic Bridge is juggling a healthy €1.4bn in assets—no small potatoes. So, let's dig...

Frederick Foundation Welcomes New Leaders for Growth

Stirring the Philanthropic Pot in Frederick Moving pieces around the community chessboard once again, the Community Foundation of Frederick County brings in fresh minds—and the stakes have never been higher for these charitable endeavors. They've just put RaeAnn E. Butler at the helm, an established presence who’s now the primary captain steering this ship. Come...